Argenica Therapeutics (ASX:AGN) is making strides towards the commercialization of a unique neuroprotective therapeutic treatment, ARG-007, aimed at mitigating the harmful effects of stroke and other acute Central Nervous System (CNS) injuries. This was revealed by the company's CEO and managing director, Dr Liz Dallimore on Wednesday.
Dr. Dalimore emphasized that the development comes in response to a need for a safe, early intervention therapeutic that can offer immediate protection to brain cells following a stroke. The goal is to provide this protection until the underlying cause of the stroke can be diagnosed and addressed, she added.
The company plans for ARG-007 to be administered by first responders in the field. This would allow for neuroprotective treatment to be given prior to a patient's arrival at the hospital, potentially leading to improved patient outcomes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.